Anti-C-MPL antibody and use thereof

ChangeBridge: Patent Grants - Peptides (C07K)

Published March 31st, 2026

Detected March 31st, 2026

Summary

USPTO granted patent US12590161B2 to Daegu Gyeongbuk Institute of Science and Technology for an anti-C-MPL antibody (2R13) that increases platelet production through megakaryocyte maturation. The antibody offers longer half-life than conventional therapeutic agents with lower self-antibody production and reduced immunogenicity. The patent covers therapeutic applications for chronic or complication-induced immune thrombocytopenia.

View original document View source feed page

What changed

USPTO granted Patent No. US12590161B2 (Kind B2) on March 31, 2026, to Daegu Gyeongbuk Institute of Science and Technology for a novel anti-C-MPL antibody (2R13). The invention relates to an antibody that increases platelet production and numbers through maturation of megakaryocytes in bone marrow. The patent includes 4 claims covering the antibody composition and its use as a therapeutic agent for thrombocytopenia. The filing date was November 9, 2021, under application number 18038497.

This patent grant is informational for entities managing intellectual property portfolios. Pharmaceutical companies and research institutions developing thrombocytopenia treatments should review the patent claims to assess potential freedom-to-operate implications. No immediate compliance actions or deadlines are required as this is a granted patent rather than a regulatory requirement. Companies with competing C-MPL antibody research should evaluate the patent scope for licensing or design-around considerations.

Source document (simplified)

← USPTO Patent Grants

Anti-C-MPL antibody and use thereof

Grant US12590161B2 Kind: B2 Mar 31, 2026

Assignee

DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventors

Kyung Moo Yea, Jee-Yeong Jeong, Sea Gwang Park, Ji Won Shin, Min-Jung Kim

Abstract

The present invention relates to a novel anti-C-MPL antibody and a use thereof, and specifically, to an anti-C-MPL antibody having an effect of increasing platelet production and its number through the maturation of megakaryocytes in the bone marrow, and a use thereof. The novel anti-C-MPL antibody (2R13) of the present invention is a polymer material and has a longer half-life than the conventional therapeutic agents, and it has the advantage of low self-antibody production and low immunogenicity as an antibody agent. In addition, it can be used as a therapeutic agent for thrombocytopenia by increasing the platelet level of patients suffering from chronic or complication-induced immune thrombocytopenia.